Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019

Pfizer offers 17 drugs to treat cancer, with four approved in the U.S. in 2017. The oncology portfolio, according to EvaluatePharma, is projected to bring in $8.3 billion in sales in 2019. For the first time, cancer drugs are expected to sell more than the cardiac and primary-care medicines.